1. Home
  2. People
  3. Faculty
  4. Mark W. Lingen

Mark W. Lingen

Professor
mark.lingen@uchospitals.edu
Research Summary
My research has focused on several basic and translational aspects of cancer biology. From a basic science perspective, my lab cloned NOL7, a novel gene that induces an anti-angiogenic phenotype and suppresses in vivo tumor growth. NOL7 acts as a master regulator of angiogenesis by modulating the expression of angiogenesis-associated mRNAs via both steady-state downregulation and posttranscriptional upregulation. NOL7 itself is positively regulated by the retinoblastoma (Rb) gene, supporting the paradigm shift that Rb can act as a positive regulator of gene transcription. Our long-term goal is to understand how transcriptional and posttranscriptional regulation of angiogenesis-related mRNAs contributes to the expression of the phenotype and to leverage this knowledge to develop novel therapeutic approaches. Our central hypothesis is that Rb positively regulates NOL7 expression and that loss of NOL7 protein expression results in decreased regulation of NOL7 target mRNA transcripts, the gain of expression of the pro-angiogenic phenotype and the loss of tumor growth inhibition. This research is innovative because it will define the mechanisms by which NOL7 acts as a master regulator of angiogenesis. Further, it provides fundamental insights into the poorly understood area of posttranscriptional regulation of angiogenesis. This research is expected to have a positive impact on human health because it may provide new therapeutic avenues for targeting angiogenesis in both physiologic and pathologic conditions. We have also been pursuing a number of translational research aspects of tumor angiogenesis using head and neck squamous cell carcinoma as a model. For example, we have been testing the hypothesis that inhibitors of angiogenesis are effective chemopreventive agents. The expression of the angiogenic phenotype is both an early and an essential step in the development of cancer, making it an attractive target for cancer prevention. The long-term goal of our work is to develop novel, nontoxic chemopreventive strategies for cancer that are based upon the inhibition of angiogenesis. These investigations have resulted in a number of clinical trials. Finally, we are currently using animal models and tissue derived from the clinical trials to investigate mechanisms of acquired resistance in response prolonged chemopreventive therapy. Such modeling will enable us to test the hypothesis that acquired resistance to inhibitors of angiogenesis can be reversed, thereby prolonging a drug’s chemopreventive activity. From a patient care perspective, I have played a leading role in defining the clinical utility of oral cancer screening adjuncts/tests. I have served on the American Dental Association (ADA) Council of Scientific Affairs (CSA). In that capacity, I was a member and Chair of CSA Expert Panels that developed evidence-based guideline recommendations for the evaluation of potentially malignant disorders of the orders of the oral cavity. In addition, I was also a member of Cochrane Systematic Reviews Expert Panels that performed systematic reviews and made clinical guideline recommendations with respect to oral cancer screening. We have also sought ways to improve our ability to diagnose, prognosticate and monitor/predict response to therapy. As such, we have been involved in large scale genomic analyses to understand how treatment of head and neck tumors influences the transcriptome. In addition, we are seeking to establish a molecularly-based saliva screening test for the identification of high-risk patients that are likely to progress to cancer. We have performed targeted sequencing to determine the mutation rate of the most commonly altered genes in moderate dysplasia, severe dysplasia, and reactive hyperplasia (control group). These analyses identified dysplasia-specific molecular changes that underlie the pathogenesis of cancer development. Using the candidate mutations identified in dysplastic tissues, we are developing assays to determine their expression levels in saliva/tissue samples from a retrospective cohort of patients with oral dysplasia with known outcomes. Finally, in the future, the dysplasia-specific biomarkers will be tested using prospective samples derived from an ongoing oral dysplasia natural history study to validate the diagnostic accuracy of a salivary screening test. These studies are conceptually innovative because they are defining the mutational landscape oral premalignancy. In addition, they will determine if diagnostic efficacy of a non-invasive molecular salivary screening platform for oral dysplasia. The research will benefit human health by improving our ability to identify the subset of molecularly/biologically important premalignant oral lesions that are likely to progress to cancer, thereby allowing for more rapid and personalized intervention when the disease is at a more treatable stage.
Keywords
Oral Cancer, Head and Neck Neoplasms, Oral Pathology, Head and neck pathology, Oral Premalignancy, Odontogenic Tumors, Salivary Gland Neoplasms, Cancer Screening, Angiogenesis
Education
  • Northwestern University, Evanston, IL, PhD Cellular & Molecular Pathology 1996
  • Northwestern University, Evanston, IL, Residency Oral & Maxillofacial Pathology 1994
  • Northwestern University, Evanston, IL, DDS Dentistry 1990
  • DePauw University, Greencastle, IN, BA Zoology 1986
Biosciences Graduate Program Association
Publications

  1. Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 Jun 05. View in: PubMed

  2. Cipriani NA, Lusardi JJ, McElherne J, Pearson AT, Olivas AD, Fitzpatrick C, Lingen MW, Blair EA. Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis. Am J Surg Pathol. 2019 Jul; 43(7):885-897. View in: PubMed

  3. Polverini PJ, Lingen MW. A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer. J Dent Res. 2019 May; 98(5):489-497. View in: PubMed

  4. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2018 Dec 01; 24(23):6099. View in: PubMed

  5. Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 Feb 01; 30(2):297-302. View in: PubMed

  6. Lingen MW. Triple O Content Innovations and New Section Editors. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Jan; 127(1):1-2. View in: PubMed

  7. Lee SS, Bindokas VP, Lingen MW, Kron SJ. Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. Lab Invest. 2018 Nov 06. View in: PubMed

  8. Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, Bell D, Lingen MW, Harichand-Herdt S, Thibo J, Zevallos J, Perez-Ordonez B. Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol. 2018 Nov 01; 36(31):3152-3161. View in: PubMed

  9. Scherpelz KP, Wong AC, Lingen MW, Taxy JB, Cipriani NA. Histological features and prognostic significance of treatment effect in lymph node metastasis in head and neck squamous cell carcinoma. Histopathology. 2019 Jan; 74(2):321-331. View in: PubMed

  10. Peterson CE, Gordon SC, Le Hew CW, Dykens JA, Jefferson GD, Tampi MP, Urquhart O, Lingen M, Watson KS, Buscemi J, Fitzgibbon ML. Society of Behavioral Medicine position statement: Society of Behavioral Medicine supports oral cancer early detection by all healthcare providers. Transl Behav Med. 2018 Jul 11. View in: PubMed

  11. Nikitakis NG, Pentenero M, Georgaki M, Poh CF, Peterson DE, Edwards P, Lingen M, Sauk JJ. Molecular markers associated with development and progression of potentially premalignant oral epithelial lesions: Current knowledge and future implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 06; 125(6):650-669. View in: PubMed

  12. Saintigny P, William WN, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM. Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3). View in: PubMed

  13. Lingen MW. Authors' response. J Am Dent Assoc. 2018 Apr; 149(4):233-234. View in: PubMed

  14. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Ceballos-López AA, Raca G, Lingen MW, Li Z, Segal JP, Churpek JE, Godley LA. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150. View in: PubMed

  15. Lingen MW, Tampi MP, Urquhart O, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Banfield L, Carrasco-Labra A. Adjuncts for the evaluation of potentially malignant disorders in the oral cavity: Diagnostic test accuracy systematic review and meta-analysis-a report of the American Dental Association. J Am Dent Assoc. 2017 Nov; 148(11):797-813.e52. View in: PubMed

  16. Lingen MW, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, Gurenlian J, Kalmar JR, Kerr AR, Lambert PM, Patton LL, Sollecito TP, Truelove E, Tampi MP, Urquhart O, Banfield L, Carrasco-Labra A. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc. 2017 Oct; 148(10):712-727.e10. View in: PubMed

  17. Can NT, Lingen MW, Mashek H, McElherne J, Briese R, Fitzpatrick C, van Zante A, Cipriani NA. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors. Head Neck Pathol. 2018 Mar; 12(1):95-104. View in: PubMed

  18. Banuelos J, Cao Y, Shin SC, Bochner BS, Avila P, Li S, Jiang X, Lingen MW, Schleimer RP, Lu NZ. Granulocyte colony-stimulating factor blockade enables dexamethasone to inhibit lipopolysaccharide-induced murine lung neutrophils. PLoS One. 2017; 12(5):e0177884. View in: PubMed

  19. Saloura V, Fatima A, Zewde M, Kiyotani K, Brisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert T, Cipriani N, Lingen M, Vokes E, Nakamura Y. Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2017 Aug 15; 23(16):4897-4907. View in: PubMed

  20. Saloura V, Vougiouklakis T, Zewde M, Deng X, Kiyotani K, Park JH, Matsuo Y, Lingen M, Suzuki T, Dohmae N, Hamamoto R, Nakamura Y. WHSC1L1-mediated EGFR mono-methylation enhances the cytoplasmic and nuclear oncogenic activity of EGFR in head and neck cancer. Sci Rep. 2017 01 19; 7:40664. View in: PubMed

  21. Polverini PJ, Lingen MW. Expanding the Research Capacity of Dental Schools: Are We There Yet? J Dent Res. 2017 01; 96(1):8-9. View in: PubMed

  22. Lingen MW. Changing of the guard. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 01; 123(1):1-2. View in: PubMed

  23. Speight PM, Epstein J, Kujan O, Lingen MW, Nagao T, Ranganathan K, Vargas P. Screening for oral cancer-a perspective from the Global Oral Cancer Forum. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Jun; 123(6):680-687. View in: PubMed

  24. Albers L, Koch EL, Lingen M, von Kries R, Brockmann K. [Transition of Adolescents with Chronic Neurologic Disorders into Adult Health Care]. Klin Padiatr. 2016 Sep; 228(5):251-6. View in: PubMed

  25. Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):21-9. View in: PubMed

  26. Saloura V, Vougiouklakis T, Zewde M, Kiyotani K, Park JH, Gao G, Karrison T, Lingen M, Nakamura Y, Hamamoto R. WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck. Oncotarget. 2016 Jul 05; 7(27):42527-42538. View in: PubMed

  27. Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734. View in: PubMed

  28. Khammanivong A, Sorenson BS, Ross KF, Dickerson EB, Hasina R, Lingen MW, Herzberg MC. Involvement of calprotectin (S100A8/A9) in molecular pathways associated with HNSCC. Oncotarget. 2016 Mar 22; 7(12):14029-47. View in: PubMed

  29. Banuelos J, Shin S, Cao Y, Bochner BS, Morales-Nebreda L, Budinger GR, Zhou L, Li S, Xin J, Lingen MW, Dong C, Schleimer RP, Lu NZ. BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis. Allergy. 2016 05; 71(5):640-50. View in: PubMed

  30. Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, Baker SC, Shulman ST, Orenstein JM, Lingen MW, Weinstock GM, Wylie TN. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015 Dec 18; 16:1076. View in: PubMed

  31. William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16. View in: PubMed

  32. Gillard M, Tom WR, Antic T, Paner GP, Lingen MW, VanderWeele DJ. Next-gen tissue: preservation of molecular and morphological fidelity in prostate tissue. Am J Transl Res. 2015; 7(7):1227-35. View in: PubMed

  33. Xiao H, Langerman A, Zhang Y, Khalid O, Hu S, Cao CX, Lingen MW, Wong DTW. Quantitative proteomic analysis of microdissected oral epithelium for cancer biomarker discovery. Oral Oncol. 2015 Nov; 51(11):1011-1019. View in: PubMed

  34. Zhong R, Bao R, Faber PW, Bindokas VP, Bechill J, Lingen MW, Spiotto MT. Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis. Cancer Res. 2015 Sep 15; 75(18):3958-3969. View in: PubMed

  35. Lingen M, Albers L, Borchers M, Haass S, Gärtner J, Schröder S, Goldbeck L, von Kries R, Brockmann K, Zirn B. Obtaining a genetic diagnosis in a child with disability: impact on parental quality of life. Clin Genet. 2016 Feb; 89(2):258-66. View in: PubMed

  36. Macey R, Walsh T, Brocklehurst P, Kerr AR, Liu JL, Lingen MW, Ogden GR, Warnakulasuriya S, Scully C. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database Syst Rev. 2015 May 29; (5):CD010276. View in: PubMed

  37. Lingen MW. Welcome R. Bryan Bell, DDS, MD, FACS, FACD. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 May; 119(5):485. View in: PubMed

  38. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. View in: PubMed

  39. Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE. Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74. View in: PubMed

  40. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. View in: PubMed

  41. Lingen MW. Triple O has gone virtual! Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jan; 119(1):1-2. View in: PubMed

  42. Ferguson BD, Tretiakova MS, Lingen MW, Gill PS, Salgia R. Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition. Growth Factors. 2014 Dec; 32(6):202-6. View in: PubMed

  43. Tower JI, Lingen MW, Seiwert TY, Langerman A. Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma. Am J Transl Res. 2014; 6(5):548-57. View in: PubMed

  44. Saloura V, Cho HS, Kiyotani K, Alachkar H, Zuo Z, Nakakido M, Tsunoda T, Seiwert T, Lingen M, Licht J, Nakamura Y, Hamamoto R. WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck. Mol Cancer Res. 2015 Feb; 13(2):293-304. View in: PubMed

  45. Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncol. 2015 Jan; 51(1):53-8. View in: PubMed

  46. Kleiber GM, Skapek SX, Lingen M, Reid RR. Odontogenic myxoma of the face: mimicry of cherubism. J Oral Maxillofac Surg. 2014 Nov; 72(11):2186-91. View in: PubMed

  47. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41. View in: PubMed

  48. Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE. DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer. PLoS One. 2014; 9(7):e102112. View in: PubMed

  49. Farah CS, Woo SB, Zain RB, Sklavounou A, McCullough MJ, Lingen M. Oral cancer and oral potentially malignant disorders. Int J Dent. 2014; 2014:853479. View in: PubMed

  50. Reindel R, Bischof J, Kim KY, Orenstein JM, Soares MB, Baker SC, Shulman ST, Perlman EJ, Lingen MW, Pink AJ, Trevenen C, Rowley AH. CD84 is markedly up-regulated in Kawasaki disease arteriopathy. Clin Exp Immunol. 2014 Jul; 177(1):203-11. View in: PubMed

  51. Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF, Cohen EE. p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One. 2014; 9(3):e90171. View in: PubMed

  52. Paral KM, Taxy JB, Lingen MW. CD34 and a smooth muscle actin distinguish verrucous hyperplasia from verrucous carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Apr; 117(4):477-82. View in: PubMed

  53. Reindel R, Kim KY, Baker SC, Shulman ST, Perlman EJ, Lingen MW, Trevenen C, Rowley AH. Periostin is upregulated in coronary arteriopathy in Kawasaki disease and is a potential diagnostic biomarker. Pediatr Infect Dis J. 2014 Jun; 33(6):659-61. View in: PubMed

  54. Walsh T, Liu JL, Brocklehurst P, Glenny AM, Lingen M, Kerr AR, Ogden G, Warnakulasuriya S, Scully C. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev. 2013 Nov 21; (11):CD010173. View in: PubMed

  55. Zhao L, Antic T, Witten D, Paner GP, Taxy JB, Husain A, Gwin K, Mirza MK, Lingen MW, Tretiakova MS. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol. 2013 Dec; 37(12):1876-81. View in: PubMed

  56. Lauxen IS, Oliveira MG, Rados PV, Lingen MW, Nör JE, Sant'ana Filho M. Immunoprofiling of oral squamous cell carcinomas reveals high p63 and survivin expression. Oral Dis. 2014 Apr; 20(3):e76-80. View in: PubMed

  57. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS. PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 2013 May; 15(5):461-71. View in: PubMed

  58. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, Fu YX. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81. View in: PubMed

  59. Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013 Jun; 49(6):525-33. View in: PubMed

  60. Reindel R, Baker SC, Kim KY, Rowley CA, Shulman ST, Orenstein JM, Perlman EJ, Lingen MW, Rowley AH. Integrins a4 and aM, collagen1A1, and matrix metalloproteinase 7 are upregulated in acute Kawasaki disease vasculopathy. Pediatr Res. 2013 Mar; 73(3):332-6. View in: PubMed

  61. Brennan PA, Wiltfang J, Samman N, Lingen MW, Hupp JR. Journal alliance to address issues of dual submission and plagiarism. Br J Oral Maxillofac Surg. 2013 Jan; 51(1):1. View in: PubMed

  62. Mankame TP, Lingen MW. The RB tumor suppressor positively regulates transcription of the anti-angiogenic protein NOL7. Neoplasia. 2012 Dec; 14(12):1213-22. View in: PubMed

  63. Samman N, Brennan PA, Wiltfang J, Lingen MW, Hupp JR. Journal alliance to address issues of dual submission and plagiarism. Int J Oral Maxillofac Surg. 2013 Jan; 42(1):1. View in: PubMed

  64. Wiltfang J, Brennan PA, Samman N, Lingen MW, Hupp JR. Journal alliance to address issues of dual submission and plagiarism. J Craniomaxillofac Surg. 2013 Jan; 41(1):1. View in: PubMed

  65. Hupp JR, Brennan PA, Lingen MW, Samman N, Wiltfang J. Journal alliance to address issues of dual submission and plagiarism. J Oral Maxillofac Surg. 2013 Jan; 71(1):3. View in: PubMed

  66. Lingen MW, Brennan PA, Wiltfang J, Samman N, Hupp JR. Journal alliance to address issues of dual submission and plagiarism. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan; 115(1):1. View in: PubMed

  67. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76. View in: PubMed

  68. Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94. View in: PubMed

  69. Doçi CL, Zhou G, Lingen MW. The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression. Oncogene. 2013 Sep 12; 32(37):4377-86. View in: PubMed

  70. Lingen MW, Szabo E. Validation of LOH profiles for assessing oral cancer risk. Cancer Prev Res (Phila). 2012 Sep; 5(9):1075-7. View in: PubMed

  71. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison ML. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013 Jan; 49(1):1-8. View in: PubMed

  72. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. Tex Dent J. 2012 May; 129(5):491-507. View in: PubMed

  73. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol. 2012 Jul; 36(7):945-54. View in: PubMed

  74. Lingen MW. Looking back as we move forward. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Jan; 113(1):1. View in: PubMed

  75. Wu X, Chen P, Sonis ST, Lingen MW, Berger A, Toback FG. A novel Peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e409-15. View in: PubMed

  76. de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Apr 15; 18(8):2336-43. View in: PubMed

  77. Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW. Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization. Clin Exp Metastasis. 2012 Jun; 29(5):397-408. View in: PubMed

  78. Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, Hu S, Arellano M, Sinha U, Le A, Messadi D, Wang M, Nabili V, Lingen M, Morris D, Randolph T, Feng Z, Akin D, Kastratovic DA, Chia D, Abemayor E, Wong DT. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev. 2012 Apr; 21(4):664-72. View in: PubMed

  79. Shoukier M, Klein N, Auber B, Wickert J, Schröder J, Zoll B, Burfeind P, Bartels I, Alsat EA, Lingen M, Grzmil P, Schulze S, Keyser J, Weise D, Borchers M, Hobbiebrunken E, Röbl M, Gärtner J, Brockmann K, Zirn B. Array CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants? Clin Genet. 2013 Jan; 83(1):53-65. View in: PubMed

  80. Doçi CL, Mankame TP, Langerman A, Ostler KR, Kanteti R, Best T, Onel K, Godley LA, Salgia R, Lingen MW. Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer. Int J Gynecol Pathol. 2012 Jan; 31(1):15-24. View in: PubMed

  81. Lingen MW. Brush-based cytology screening in the tonsils and cervix: there is a difference! Cancer Prev Res (Phila). 2011 Sep; 4(9):1350-2. View in: PubMed

  82. Chen P, Lingen M, Sonis ST, Walsh-Reitz MM, Toback FG. Role of AMP-18 in oral mucositis. Oral Oncol. 2011 Sep; 47(9):831-9. View in: PubMed

  83. Glubb DM, Cerri E, Giese A, Zhang W, Mirza O, Thompson EE, Chen P, Das S, Jassem J, Rzyman W, Lingen MW, Salgia R, Hirsch FR, Dziadziuszko R, Ballmer-Hofer K, Innocenti F. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67. View in: PubMed

  84. Liu J, Kuo WL, Seiwert TY, Lingen M, Ciaccio MF, Jones RB, Rosner MR, Cohen EE. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin. Head Neck. 2011 Dec; 33(12):1774-82. View in: PubMed

  85. Lingen MW, Pinto A, Mendes RA, Franchini R, Czerninski R, Tilakaratne WM, Partridge M, Peterson DE, Woo SB. Genetics/epigenetics of oral premalignancy: current status and future research. Oral Dis. 2011 Apr; 17 Suppl 1:7-22. View in: PubMed

  86. Lingen MW. Assuring dental student head and neck cancer screening competency. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Mar; 111(3):267-8. View in: PubMed

  87. Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila). 2011 Feb; 4(2):230-7. View in: PubMed

  88. Zhou G, Hasina R, Wroblewski K, Mankame TP, Doçi CL, Lingen MW. Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis. Cancer Prev Res (Phila). 2010 Nov; 3(11):1493-502. View in: PubMed

  89. Zhou G, Doçi CL, Lingen MW. Identification and functional analysis of NOL7 nuclear and nucleolar localization signals. BMC Cell Biol. 2010 Sep 27; 11:74. View in: PubMed

  90. Lingen MW. Screening for oral premalignancy and cancer: what platform and which biomarkers? Cancer Prev Res (Phila). 2010 Sep; 3(9):1056-9. View in: PubMed

  91. Lingen MW. Can saliva-based HPV tests establish cancer risk and guide patient management? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Sep; 110(3):273-4. View in: PubMed

  92. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2010 Jul 10; 28(20):3336-43. View in: PubMed

  93. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, Flaitz CM, Graham FJ, Hujoel PP, Kalmar JR, Koch WM, Lambert PM, Lingen MW, Oettmeier BW, Patton LL, Perkins D, Reid BC, Sciubba JJ, Tomar SL, Wyatt AD, Aravamudhan K, Frantsve-Hawley J, Cleveland JL, Meyer DM. Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc. 2010 May; 141(5):509-20. View in: PubMed

  94. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, Li J, Hasina R, Cheng C, Lingen MW, Gerstein MB, Weichselbaum RR, Xing HR, Lussier YA. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol. 2010 Apr 01; 6(4):e1000730. View in: PubMed

  95. Lingen MW. Pragmatics versus contrarians: how does one resolve their differences with respect to oral cancer screening? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Mar; 109(3):325-6. View in: PubMed

  96. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64. View in: PubMed

  97. Mankame TP, Zhou G, Lingen MW. Identification and characterization of the human NOL7 gene promoter. Gene. 2010 May 15; 456(1-2):36-44. View in: PubMed

  98. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010 Mar; 17(3):499-512. View in: PubMed

  99. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR. A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. Blood. 2009 Nov 12; 114(20):4592-600. View in: PubMed

  100. Lingen MW. Point of care salivary diagnostics for systemic disease screening: if someone builds it, will dentistry come? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Sep; 108(3):309-10. View in: PubMed

  101. Hasina R, Martin LE, Kasza K, Jones CL, Jalil A, Lingen MW. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila). 2009 Apr; 2(4):385-93. View in: PubMed

  102. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31. View in: PubMed

  103. Lingen MW. Direct-to-consumer advertising for oral cancer screening devices. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Mar; 107(3):299-300. View in: PubMed

  104. Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009 Jan 01; 69(1):65-74. View in: PubMed

  105. Lingen MW. The changing face of head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep; 106(3):315-6. View in: PubMed

  106. Lingen MW. Cause-related marketing: the uneasy alliance between altruism and corporate greed. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Apr; 105(4):407-9. View in: PubMed

  107. Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008 Apr; 88(4):342-53. View in: PubMed

  108. Radhakrishnan R, Solomon M, Satyamoorthy K, Martin LE, Lingen MW. Tissue microarray - a high-throughput molecular analysis in head and neck cancer. J Oral Pathol Med. 2008 Mar; 37(3):166-76. View in: PubMed

  109. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, Loganathan S, Kanteti R, Reichman T, Nallasura V, Schwartz S, Faoro L, Wang YC, Girard L, Tretiakova MS, Ahmed S, Zumba O, Soulii L, Bindokas VP, Szeto LL, Gordon GJ, Bueno R, Sugarbaker D, Lingen MW, Sattler M, Krausz T, Vigneswaran W, Natarajan V, Minna J, Vokes EE, Ferguson MK, Husain AN, Salgia R. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res. 2008 Jan 01; 68(1):132-42. View in: PubMed

  110. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Lingen M, Strieter RM, Nunez G, Nör JE. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res. 2007 Oct 15; 67(20):9685-93. View in: PubMed

  111. Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008 Jan; 44(1):10-22. View in: PubMed

  112. Lingen MW. Improving translational research for oral cancer screening aids: putting my "money" where my mouth is. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Sep; 104(3):301-2. View in: PubMed

  113. Hong J, Doebele RC, Lingen MW, Quilliam LA, Tang WJ, Rosner MR. Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. J Biol Chem. 2007 Jul 06; 282(27):19781-7. View in: PubMed

  114. Lingen MW. Oral cancer screening aids: where is the science? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb; 103(2):153-4. View in: PubMed

  115. Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, Lingen MW. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep; 11(1):16-29. View in: PubMed

  116. Lingen MW. Tales of academic dishonesty and what do we do about it? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct; 102(4):429-30. View in: PubMed

  117. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006 Jul-Sep; 72(1-2):3-11. View in: PubMed

  118. Cohen EE, Lingen MW, Zhu B, Zhu H, Straza MW, Pierce C, Martin LE, Rosner MR. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006 Jun 15; 66(12):6296-303. View in: PubMed

  119. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9. View in: PubMed

  120. Antico G, Lingen MW, Sassano A, Melby J, Welch RW, Fiore S, Pilon AL, Miele L. Recombinant human uteroglobin/CC10 inhibits the adhesion and migration of primary human endothelial cells via specific and saturable binding to fibronectin. J Cell Physiol. 2006 May; 207(2):553-61. View in: PubMed

  121. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DW. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8. View in: PubMed

  122. Hasina R, Pontier AL, Fekete MJ, Martin LE, Qi XM, Brigaudeau C, Pramanik R, Cline EI, Coignet LJ, Lingen MW. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene. 2006 Jan 26; 25(4):588-98. View in: PubMed

  123. Hasina R, Lingen MW. Head and neck cancer: the pursuit of molecular diagnostic markers. Semin Oncol. 2004 Dec; 31(6):718-25. View in: PubMed

  124. Vokes EE, Lingen MW. Update in head and neck oncology. Semin Oncol. 2004 Dec; 31(6):717. View in: PubMed

  125. Petro BJ, Tan RC, Tyner AL, Lingen MW, Watanabe K. Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium. Oral Oncol. 2004 Nov; 40(10):1040-7. View in: PubMed

  126. Nickoloff BJ, Lingen MW, Chang BD, Shen M, Swift M, Curry J, Bacon P, Bodner B, Roninson IB. Tumor suppressor maspin is up-regulated during keratinocyte senescence, exerting a paracrine antiangiogenic activity. Cancer Res. 2004 May 01; 64(9):2956-61. View in: PubMed

  127. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol. 2004 May 01; 22(9):1743-52. View in: PubMed

  128. Dettin M, Bicciato S, Scarinci C, Cline E, Lingen MW, Di Bello C. Synthetic peptides derived from the angiostatin K4 domain inhibit endothelial cell migration. Chembiochem. 2003 Nov 07; 4(11):1238-42. View in: PubMed

  129. Lingen MW. Endothelial cell migration assay. A quantitative assay for prediction of in vivo biology. Methods Mol Med. 2003; 78:337-47. View in: PubMed

  130. Kuo WP, Hasina R, Ohno-Machado L, Lingen MW. Classification and identification of genes associated with oral cancer based on gene expression profiles. A preliminary study. N Y State Dent J. 2003 Feb; 69(2):23-6. View in: PubMed

  131. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 2003 Feb 01; 63(3):555-9. View in: PubMed

  132. Cline EI, Bicciato S, DiBello C, Lingen MW. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res. 2002 Dec 15; 62(24):7143-8. View in: PubMed

  133. Kuo WP, Jenssen TK, Park PJ, Lingen MW, Hasina R, Ohno-Machado L. Gene expression levels in different stages of progression in oral squamous cell carcinoma. Proc AMIA Symp. 2002; 415-9. View in: PubMed

  134. Todd R, Lingen MW, Kuo WP. Gene expression profiling using laser capture microdissection. Expert Rev Mol Diagn. 2002 Sep; 2(5):497-507. View in: PubMed

  135. Liss C, Fekete MJ, Hasina R, Lingen MW. Retinoic acid modulates the ability of macrophages to participate in the induction of the angiogenic phenotype in head and neck squamous cell carcinoma. Int J Cancer. 2002 Jul 20; 100(3):283-9. View in: PubMed

  136. Wei PC, Laurell L, Lingen MW, Geivelis M. Acellular dermal matrix allografts to achieve increased attached gingiva. Part 2. A histological comparative study. J Periodontol. 2002 Mar; 73(3):257-65. View in: PubMed

  137. Curry JL, Petruzzelli GJ, McClatchey KD, Lingen MW. Synchronous benign and malignant salivary gland tumors in ipsilateral glands: a report of two cases and a review of literature. Head Neck. 2002 Mar; 24(3):301-6. View in: PubMed

  138. Matthies AM, Low QE, Lingen MW, DiPietro LA. Neuropilin-1 participates in wound angiogenesis. Am J Pathol. 2002 Jan; 160(1):289-96. View in: PubMed

  139. Hasina R, Lingen MW. Angiogenesis in oral cancer. J Dent Educ. 2001 Nov; 65(11):1282-90. View in: PubMed

  140. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001 Sep; 93(6):781-5. View in: PubMed

  141. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001 Jun 15; 97(12):3919-24. View in: PubMed

  142. Lingen M, Sturgis EM, Kies MS. Squamous cell carcinoma of the head and neck in nonsmokers: clinical and biologic characteristics and implications for management. Curr Opin Oncol. 2001 May; 13(3):176-82. View in: PubMed

  143. Sommercorn LM, Di Fiore PM, Dixit SN, Koerber A, Lingen MW, Veis A. Effect of alendronate on immature human dental root explants. J Endod. 2000 Mar; 26(3):133-7. View in: PubMed

  144. Lingen MW. Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch Pathol Lab Med. 2001 Jan; 125(1):67-71. View in: PubMed

  145. Lingen MW, Emami B, Clark JI. New therapeutic strategies for the treatment and prevention of head and neck cancer. Expert Opin Investig Drugs. 2000 Dec; 9(12):2855-72. View in: PubMed

  146. Wei PC, Laurell L, Geivelis M, Lingen MW, Maddalozzo D. Acellular dermal matrix allografts to achieve increased attached gingiva. Part 1. A clinical study. J Periodontol. 2000 Aug; 71(8):1297-305. View in: PubMed

  147. Lingen MW, Chang KW, McMurray SJ, Solt DB, Kies MS, Mittal BB, Haines GK, Pelzer HJ. Overexpression of p53 in squamous cell carcinoma of the tongue in young patients with no known risk factors is not associated with mutations in exons 5-9. Head Neck. 2000 Jul; 22(4):328-35. View in: PubMed

  148. Lingen MW. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit Rev Oral Biol Med. 1999; 10(2):153-64. View in: PubMed

  149. Dardick I, Birek C, Lingen MW, Rowe PE. Differentiation and the cytomorphology of salivary gland tumors with specific reference to oncocytic metaplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Dec; 88(6):691-701. View in: PubMed

  150. Bentz BG, Haines GK, Lingen MW, Pelzer HJ, Hanson DG, Radosevich JA. Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Ann Otol Rhinol Laryngol. 1999 Aug; 108(8):781-7. View in: PubMed

  151. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res. 1998 Dec 01; 58(23):5551-8. View in: PubMed

  152. Lingen MW. Understanding the biology of oral cancer and chemoprevention. CDS Rev. 1998 May-Jun; 91(4):24-8. View in: PubMed

  153. Lingen M, Hengerer F, Falke D. Mixed vaginal infections of Balb/c mice with low virulent herpes simplex type 1 strains result in restoration of virulence properties: vaginitis/vulvitis and neuroinvasiveness. Med Microbiol Immunol. 1997 Mar; 185(4):217-22. View in: PubMed

  154. Lingen MW. Teaching oral pathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Mar; 83(3):308. View in: PubMed

  155. Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis. 1997 Feb; 18(2):329-38. View in: PubMed

  156. Lingen M, Seck T, Weise K, Falke D. Single amino acid substitutions in the glycoprotein B carboxy terminus influence the fusion from without property of herpes simplex virus type 1. J Gen Virol. 1995 Jul; 76 ( Pt 7):1843-9. View in: PubMed

  157. Lingen M, Seck T, Weise K, Falke D. Two mutations in gB-1 and gD-1 of herpes simplex virus type 1 are involved in the "fusion from without" phenotype in different cell types. Virus Genes. 1996; 13(3):221-8. View in: PubMed

  158. Seck T, Koch O, Lingen M, Falke D. Influence of glycoproteins B, C and D on the conversion of virus-to-cell attachment from heparin sensitivity to resistance. Acta Virol. 1996 Sep; 40(4):179-85. View in: PubMed

  159. Lingen MW, Polverini PJ, Bouck NP. Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells. Lab Invest. 1996 Feb; 74(2):476-83. View in: PubMed

  160. Janette A, Pecaro B, Lonergan M, Lingen MW. Solitary intraoral keratoacanthoma: report of a case. J Oral Maxillofac Surg. 1996 Aug; 54(8):1026-30. View in: PubMed

  161. Lingen M, Seck T, Dehoust U, Weise K, Falke D. Amino acid substitutions in glycoprotein D mediate the ability of fusion from without-positive herpes simplex virus type 1 strains to penetrate at 4 degrees and in the presence of soluble glycoprotein D. Intervirology. 1995; 38(5):283-9. View in: PubMed

  162. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996 Aug 01; 98(3):671-9. View in: PubMed

  163. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol. 1996 Jul; 149(1):247-58. View in: PubMed

  164. Lingen MW, Solt DB, Polverini PJ. Unusual presentation of a chondromyxoid fibroma of the mandible. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol. 1993 May; 75(5):615-21. View in: PubMed

  165. Walev I, Lingen M, Lazzaro M, Weise K, Falke D. Cyclosporin A resistance of herpes simplex virus-induced "fusion from within" as a phenotypical marker of mutations in the Syn 3 locus of the glycoprotein B gene. Virus Genes. 1994 Jan; 8(1):83-6. View in: PubMed

  166. Seck T, Lingen M, Weise K, Falke D. Evidence for a multistep mechanism for cell-cell fusion by herpes simplex virus with mutations in the syn 3 locus using heparin derivatives during fusion from within. Arch Virol. 1994; 136(1-2):173-81. View in: PubMed

  167. Lingen MW, Rao SM, Hutten MC, Pelzer HJ. Primary ectopic meningioma of the maxillary sinus: case report and review of the literature. Head Neck. 1995 May-Jun; 17(3):258-62. View in: PubMed

  168. Lingen MW, Mostofi RS, Solt DB. Myofibromas of the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Sep; 80(3):297-302. View in: PubMed
© 2019 The University of Chicago | All Rights Reserved.
Facebook Twitter Youtube